PubMed Health⌕ Search

Biomedical subjects

P O Warner

Publications and source records attributed to P O Warner.

11 recordsLinked to original sources
PubMed1990

Measurement and impact of agricultural odors from a large scale swine production farm.

With the move on a nationwide scale to greater centralization and specialization of swine production and consequent swine confinement, rural communities face the prospects of increasing odor impact from these sources. The enactment of regulations to prevent community odor nuisance requires the establishment of limits to reflect emissions which may be found to exceed such community standards. While urban industrial sources of odor such as rendering plants and coke ovens are required to meet source emission limits as a result of citizen complaint related litigation, agricultural sources are, in most states, exempt from such legal restrictions. However, should a burden of nuisance complaints come into evidence, data showing individual source emission measurements of these new upscaled livestock facilities as odor sources is of great importance. This study of a 50,000 animal swine-growing facility show that the greatest odor impact originates from the gestation buildings (1,200,00 ou/min), nursery buildings (630,000 ou/min) and field sprinklers (334, 156 ou/min). As shown by a comparison of urban odor source related citizen complaint data versus source measurement results and types of successful abatement actions on an urban scale, an air scrubber system to serve these buildings together with the substitution of ground injection to replace field sprinkling of liquid waste would be expected to achieve the improvement in odor control comparable to urban industrial sources with similar reduction or elimination of odor complaints.

Air Pollution↗
PubMed1983

Sampling and analytical determination of airborne N,N-dimethylcyclohexylamine.

A method has been developed for the collection on a reactive surface and subsequent analytical determination of airborne N,N-dimethylcyclohexylamine (DMCA). DMCA from ambient or test atmosphere is collected on a Tenax sorbent sample tube treated with hydrochloric acid (HCl) using a low flow, personal sampling pump. The Tenax sorbent sample tube is desorbed with tetrahydrofuran (THF) and sodium hydroxide (NaOH) and the resulting solution is analyzed on a gas chromatograph/mass spectrometer (GC/MS) using selected ion monitor. The peak areas for ions 84 and 127 are integrated and compared to standards. It is shown that collected samples are stable at room temperature for more than 50 days. This method was proven in the laboratory using concentrations in air from 1.0 ppm to 4.1 ppm.

Air↗
PubMed1975

Measurement of the influence of a cement kiln stack on a surrounding residential community by injection of an identification particulate.

An identification particulate, barium sulfate, was injected into the kiln stack of a large cement plant in order to determine the effect of the particulate effluent of this stack on the immediately surrounding residential community. Meteorological conditions at the time of the injection favored deposition of the stack plume fallout directly over the location of a 7.75-km2 area in which both dustfall and suspended particle samplers were located. Dustfall data are reported for a 24-hour period to permit collection of all possible BaSO4-relatable stack emission. Collected particulate was analyzed for calcium and barium by atomic absorption spectroscopy. Collected dustfall particulates showed no stack effluent effect; collected suspended particulates exhibited a content of stack-relatable material in the amount of 1% of the total observed weight.

Air Movements↗
PubMed1975

Micronized 17 beta-estradiol for oral estrogen therapy in menopausal women.

Micronized 17beta-estradiol (E2) was used as oral replacement therapy in 369 patients with estrogen deficiency and related menopausal symptoms. Over 95 percent of 319 patients evaluable for efficacy gained satisfactory relief of their symptoms from cyclic (on 21 days/off 7 days) E2 therapy. Approximately 77 percent required no adjustment of their initial daily dose, viz, 1 mg (5 or less hot flushes per day) or 2 mg (6 or more flushes daily). In addition, 80 percent (58/72) of the patents who did not obtain adequate control from their starting dose were successfully titrated, either upward to a maximum of 4 mg/day or downward for maintenance. Overall, a higher percentage of patients were treated successfully with 2 mg daily (209/319; 66 percent) than with 1 mg/day (22 percent). About 8 percent of the patients required 3 or 4 mg daily, while 4 percent failed to derive adequate benefit from micronized E2. Oral E2 therapy was well tolerated; hence, the attrition rate due to side effects or lack of control was only 6 percent (22/369). Moreover, all laboratory fingings were within normal limits, even in patients treated with E2 for over 12 months. Coincidental endometrial changes were found in 9 patients, all of whom had received long-term (9 months-3 years) estrogen therapy prior to entering this study. Thus, the stste of the endometrium should be determined before any estrogens are given for the monopause. It is concluded that micronized E2 is highly efficacious, well accepted, and safe for oral estrogen-replacement therapy in menopausal women.

Administration, Oral↗